News Article | May 16, 2017
— Esophageal Cancer - Pipeline Market Review, H1 2017 is a new report added to ReportsnReports.com. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Browse the 85 Tables and 11 Figures, 16 Company Profiles, Spread across 493 Pages Report Available at http://www.reportsnreports.com/reports/992867-esophageal-cancer-pipeline-review-h1-2017.html . Drug Profiles of Esophageal Cancer - 1-BB1, ADCT-502, ADXS-HER2, afatinib dimaleate, AL-3818, ALM-301, apatinib, APR-246, atezolizumab, ATL-101, BGBA-317, binimetinib, brontictuzumab, CBT-501, CDX-1401 many more. Main Companies are Adaptimmune Therapeutics Plc, ADC Therapeutics Sar, Aduro BioTech Inc, Advaxis Inc, Advenchen Laboratories LLC , Almac Discovery Ltd, Amgen Inc , Aprea AB , ArQule Inc , Array BioPharma Inc , Aslan Pharmaceuticals Pte Ltd , ATLAB Pharma SAS , Bayer AG , BeiGene Ltd , Beta Pharma Inc , Boehringer Ingelheim GmbH , Bristol-Myers Squibb Company , CBT Pharmaceuticals Inc , Celgene Corp , Celldex Therapeutics Inc, Cellectar Biosciences Inc, CellSeed Inc , Clovis Oncology Inc , Cyclacel Pharmaceuticals Inc , Eli Lilly and Company , F. Hoffmann-La Roche Ltd , Genmab A/S , GlaxoSmithKline Plc, Glycotope GmbH , Hutchison China MediTech Ltd , Ignyta Inc , Immunocore Ltd, ImmunoFrontier Inc , Immunomedics Inc , Intezyne Technologies Inc , Jiangsu Hengrui Medicine Co Ltd , Johnson & Johnson , Komipharm International Co Ltd , Leap Therapeutics Inc , MaxiVAX SA , Mebiopharm Co Ltd , MedImmune LLC , Merck & Co Inc , Novartis AG , Omeros Corp , Oncolys BioPharma Inc , OncoMed Pharmaceuticals Inc , Ono Pharmaceutical Co Ltd , Puma Biotechnology Inc, Rhizen Pharmaceuticals SA , Shionogi & Co Ltd , Spectrum Pharmaceuticals Inc , Stelic Institute & Co Inc , Supratek Pharma Inc 63, Symphogen A/S 63, Taiho Pharmaceutical Co Ltd 64, Taiwan Liposome Company Ltd 64, Takara Bio Inc 65, Transgene Biotek Ltd 65, VioQuest Pharmaceuticals Inc 66, XuanZhu Pharma Co Ltd. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=992867. Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery. The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 33, 28, 2, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 5, 2 and 1 molecules, respectively. Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope • The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology). • The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology) About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the For more information, please visit http://www.reportsnreports.com/reports/992867-esophageal-cancer-pipeline-review-h1-2017.html
Cardoen G.,Intezyne |
Burke B.,Intezyne |
Sill K.,Intezyne |
Journal of Polymer Research | Year: 2012
A heterobifunctional polyethylene glycol (PEG) derivative possessing both "click" and electrophilic functionalities was prepared for use in bioconjugation applications. We utilized a dibenzyl-protected amine functional initiator to prepare high purity amino-PEG-alcohol by the polymerization of ethylene oxide. Subsequent chain-end modification of the heterobifunctional PEG afforded the desired N-hydroxy succinimidyl-PEG-azide derivative in 33% overall yield. This PEG derivative allows for versatile bioconjugation chemistry where activated ester chemistry and "click" chemistry can be selectively performed, an area of orthogonal bioconjugation that has not previously been accessible. © Springer Science+Business Media B.V. 2012.
Mirosevich J.,Intezyne |
Cardoen G.,Intezyne |
Burke B.,Intezyne |
Costich T.,Intezyne |
Journal of Polymer Science, Part A: Polymer Chemistry | Year: 2012
Cationic polymers have received much attention as promising nonviral vectors for gene transfer. However, development of polymers with low cell toxicities and high transfection efficiencies continue to be a significant problem and a major hurdle to their success. Poly-D/L aspartate- diethylenetriamine poly(D/L Asp-DET) polymers were synthesized and evaluated as nonviral gene delivery agents. Poly(D/L Asp-DET) polymers display endosome buffering capacity. The polymers condense plasmid DNA above N:P ratios of 1 and form polyplex particles of ∼50-100 nm, with zeta potentials between neutral and +40 mV. Transmission electron microscopy shows the polyplexes to be uniform in size and shape. Polyplexes maintain the structural integrity of DNA following incubation in nucleases and also show high transfection efficiencies with minimal toxicity in both HCT-116 and PC-3 cell culture. However, it is found that these poly(D/L Asp-DET)/DNA polyplexes immediately aggregate in salt and serum conditions, making them unsuitable for use in vivo. Therefore, the polyplexes were further modified by covalent addition of polyethylene glycol (PEG). Introduction of this second step produces PEG-polyplexes of uniform size (below 100 nm), with neutral zeta potentials that are also stable in both salt and serum conditions. These results suggest poly(D/L Asp-DET) cationic polymers as potentially safe and efficient nonviral gene delivery agents. © 2011 Wiley Periodicals, Inc.